Benralizumab 30 mg + Matched placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nasal Polyposis
Conditions
Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
Trial Timeline
Nov 25, 2019 → Apr 7, 2025
NCT ID
NCT04157335About Benralizumab 30 mg + Matched placebo
Benralizumab 30 mg + Matched placebo is a phase 3 stage product being developed by AstraZeneca for Nasal Polyposis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04157335. Target conditions include Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04157335 | Phase 3 | Terminated |
Competing Products
20 competing products in Nasal Polyposis